Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SAN DIEGO, June 01, 2017 -- Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women's reproductive health, today announced that Sabrina Martucci Johnson, Daré Founder and CEO, will present at the LD Micro Invitational Conference on Wednesday, June 7, 2017, at 7:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, California.
“Daré’s product candidate, Ovaprene®, is a clinical stage, non-hormonal contraceptive ring for monthly use,” said Ms. Johnson. “Since the approval of the birth control pill by the FDA in 1960, most innovation has focused on hormones. If approved, Ovaprene would address an unmet need because it is a non-hormonal monthly option. The only contraceptive ring on the market is a hormonal contraceptive ring, NuvaRing®, with 2016 sales of $777 million.”
About Daré Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. Daré believes there is an unmet need in the United States, in other developed countries, and in developing countries, for innovative product candidates that expand options, improve outcomes and are easy to use. Product development in women's reproductive health is fragmented, creating a potential opportunity for Daré. Daré’s goal is to fill the gap by taking products from innovation through development. The Daré team is well-suited to ensure these products advance and are one day commercially available. The founders bring experience in global women's healthcare as well as success in prior ventures in funding, achieving regulatory approvals, partnering, and launching a number of products, including devices, therapeutics and diagnostics.
For more information on Daré, please visit www.darebioscience.com.
Contact: Sabrina Johnson 858-769-9145 [email protected]
